ClinicalTrials.gg
CompletedNCT00795158Updated Feb 17, 2022

How Desloratadine (Clarinex, Aerius) Affects Quality of Life in Patients With Chronic Idiopathic Urticaria (Have Had Hives for 6 Weeks or Longer)(Study P02988)

A Phase 3 interventional study of desloratadine in Urticaria, sponsored by Organon and Co. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-02-17.

Sponsored by Organon and Co · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
282
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing desloratadine in Urticaria — none open to participants now, none under way, none of them phase 3. desloratadine · Urticaria.

Enrollment
Largest of 10
282 · median 139
Started
2002
the only one that year
Phase 3
3 of 10
none open now
Registered
7th of 10
by date
Lead sponsor
6 of 10
Organon and Co

Among the 10 studies testing desloratadine in Urticaria, this one has the largest enrollment, is the only one that started in 2002, is one of 3 in phase 3, and was the 7th registered.

Urticaria

148 studies on the registry are indexed under Urticaria; 20 are open to participants now.

Browse Urticaria studies →

Open to participants now

None of the 10 studies testing desloratadine in Urticaria is open now. The open studies under Urticaria, anywhere →

Where they have run

About desloratadine

desloratadine: first FDA approval 2001 (CLARINEX), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 12 Urticaria studies recruiting now, 3 (25%) set no upper age limit and 6 (50%) stop at 75 or younger; 6 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing desloratadine in Urticaria as a file.
02

Study summary

The purpose of this study was to determine the effect of desloratadine treatment on quality of life, daytime functioning, quality of sleep, symptoms, and disease severity in patients who had hives for 6 weeks or longer. Patients took desloratadine for 1 month. Once a week, patients filled out a questionnaire to tell how their hives affected their lives. This questionnaire is called the Dermatology Life Quality Index or DLQI. They also filled out a diary every day to tell how much itching they had, how many hives they had, and how their hives had affected their sleep or daily activities. The patients and doctors rated the patients' overall condition and how much relief patients got from treatment.

03

Conditions studied

  • Urticaria

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must demonstrate their willingness to participate into the study and comply with its procedures by signing a written .
  • Subjects must be >=18 years of age, of either sex and any race.
  • Women of (includes women who are less than 1 year ) must be using an acceptable method of since at least one month prior to visit 1 (e.g., hormonal contraceptive, medically prescribed IUD, condom in combination with spermicide) or be surgically sterilized (e.g., hysterectomy or tubal ligation). Women of childbearing potential should be counseled in the appropriate use of birth control while in this study.
  • Subjects must be in general good health as confirmed by medical history and, physical examination; i.e., they must be free of any disease (other than chronic urticaria [CU]) that would interfere with study evaluations.
  • Subjects must understand and be able to adhere to the dosing and visit schedules, and agree to complete the questionnaires and to record accurately and consistently in a daily diary symptom severity scores, medication times, concomitant medications, and adverse events.
  • Subjects must have a history of CU defined as at least 6 weeks of pruritus and hives with hives lasting less than 24 hours and occurring at least 2 days per week.
  • Subjects must be experiencing a current CU flare with hives present at least 2 days in the week prior to the consent visit/visit 1.
  • Subjects must have a pruritus score >=2 and a hive score >=1 at consent visit/Visit 1 or during the 12 hours before the consent visit/Visit 1
  • Subjects must score the Overall Condition of CU >=2 at both consent visit/Visit 1 and Visit 2 (Baseline).
  • Subjects must have a total pruritus score of >=11 for the sum of morning (AM) and evening (PM) (reflective) diary scores for the 3 days prior to Visit 2 (Baseline) plus the morning score on the day of Visit 2
  • Women of childbearing potential must have a negative urine pregnancy test at Visit 2 (Baseline).

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant or nursing.
  • Subjects who have not observed the designated for any of the prohibited medications
  • Subjects with asthma
  • Subjects with drug or food allergies that manifest as skin reactions during 1 year prior to consent visit / visit 1
  • Subjects with atopic dermatitis
  • Subjects with urticaria that is primarily due to physical urticaria or other known etiology (on the basis of clinical history and physical examination).
  • Subjects with CU unresponsive to antihistamines.
  • Subjects under regular treatment with NSAIDs.
  • Subjects who have been hospitalized because of worsening in their CU within 3 months prior to Visit 1 (Screening).
  • Subjects with a history of to Desloratadine or any of its .
  • Subjects previously enrolled into this study (i.e. who have been assigned to treatment).
  • Subjects who are staff personnel directly involved with the administration of this study.
  • Subjects who have any metabolic, cardiovascular, immunologic, neurologic, hematologic, neoplastic, gastrointestinal, cerebrovascular, or respiratory disease, or any other disorder which, in the judgment of the Investigator, may interfere with the study evaluations or affect subject safety.
  • Subjects with a history of psychosis, antagonistic personality, poor motivation, hypochondriasis, or any other emotional or intellectual problems that are likely to limit the validity of consent to participate in the study.
  • Subjects with a history of noncompliance with medications or treatment protocols.
  • Subject treated with any drug in the last 30 days prior to baseline
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
282 participants (actual)

Study arms

  • Experimental
    Arm 1

    Drug: desloratadine

Interventions

  • desloratadine 5 mg tablets; one tablet orally once a day for 28 days

    Also known as: Clarinex; Aerius; SCH 34117; descarboethoxyloratadine

06

What researchers measure

Primary outcomes

  1. Change from baseline to day 28 in Dermatology Life Quality Index (DLQI) score

    Time frame: Baseline and treatment day 28

Secondary outcomes

  1. Change from Baseline in the DLQI score on treatment days 7, 14, 21

    Time frame: Baseline and treatment days 7, 14, 21

  2. Change from Baseline in pruritus, the number of hives, sleep quality, and daily activity impairment on treatment days 7, 14, 21, and 28

    Time frame: Baseline and treatment days 7, 14, 21, and 28

  3. Change from Baseline in the Overall Condition of chronic urticaria on treatment days 14 and 28

    Time frame: Baseline and treatment days 14 and 28

  4. Percent of subjects who rate their response to therapy as either Complete, Marked, or Moderate Relief on treatment days 14 and 28

    Time frame: Treatment days 14 and 28

  5. Evaluation of tolerability and safety by clinical laboratory tests

    Time frame: Baseline and treatment day 28

  6. Evaluation of tolerability and safety by adverse events

    Time frame: Screening, Baseline, and treatment days 14 and 28

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Seidenari S, Cirillo A, Amoroso S, Flori ML, Amerio P, Ricciuti E, Vena GA, Berardesca E, Le Grazie C and the Italian Study Group on Desloratadine (DL) in Chronic Urticaria. Desloratadine 5 milligrams once daily improves quality of life in chronic idiopathic urticaria. G Ital Dermatol Venereol. 2006;141(3):207-214
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2002, a primary completion of Jan 2004 and a completion of Jan 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2008
First posted
Nov 21, 2008
Start
Nov 2002
Primary completionActual
Jan 2004
CompletionActual
Jan 2004
Last update
Feb 17, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00795158
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Nov 21, 2008
Start date
Nov 2002
Primary completion
Jan 2004
Completion
Jan 2004
Last update
Feb 17, 2022

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Desloratadine

Start the discussion